Japan Health Panel Finds No Causal Link Between Tamiflu, Abnormal Behavior (Japan)
This article was originally published in PharmAsia News
Executive Summary
Researchers at Japan's Ministry of Health, Labor and Welfare found no causal link between Roche's anti-flu drug Tamiflu (oseltamivir phosphate) and incidents of abnormal behavior. The group surveyed physicians and relatives of 10,000 flu patients 18 years old and younger, and found 79.3 percent of them took the drug. The survey disclosed symptoms of abnormal behavior in 9.7 percent of patients given Tamiflu and 22 percent of those who did not take the drug. The leader of the researchers cautioned no conclusion could be made until the results are analyzed further. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.